ArticleCureus2025
Role of Saroglitazar in Improving Transient Elastography Parameters in Significant and Advanced Metabolic Dysfunction-Associated Steatohepatitis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMetabolic dysfunction-associated steatohepatitis (MASH) contributes significantly to liver-related and cardiometabolic morbidity. Saroglitazar, a dual peroxisome proliferator-activated receptor (PPAR)-α/γ agonist, targets both hepatic and metabolic pathways. This study evaluated its real-world efficacy in improving liver stiffness, steatosis, hepatic transaminases, and lipid parameters.
methodsThis retrospective, single-center, observational study included 204 adults with metabolic dysfunction-associated steatotic liver disease (MASLD)/MASH treated with saroglitazar 4 mg once daily for 52 weeks. Patients were categorized as Significant Fibrosis (<14 kPa; n = 104) or Advanced Fibrosis (≥14 kPa; n = 100) based on baseline liver stiffness measurement (LSM). Changes in LSM, controlled attenuation parameter (CAP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol, and low-density lipoprotein cholesterol (LDL-C) were analyzed at baseline, 24 weeks, and 52 weeks.
resultsIn the Significant Fibrosis group, mean LSM reduced from 10.31 ± 2.01 to 6.27 ± 1.44 kPa (-39.1%, p < 0.001) and CAP from 295.82 ± 49.34 to 241.01 ± 63.61 dB/m (-18.4%). ALT and AST declined by 49.5% and 43.4%, respectively, with total cholesterol and LDL-C reductions of 17.6% and 25.9%. In the Advanced Fibrosis group, LSM decreased from 17.96 ± 1.85 to 13.83 ± 1.42 kPa (-23.0%) and CAP from 317.05 ± 61.28 to 272.36 ± 52.38 dB/m (-14.1%), accompanied by ALT and AST reductions of 46.6% and 45.1%, and total cholesterol and LDL-C reductions of 18.3% and 25.7% (p < 0.001 for all). Saroglitazar was well-tolerated without serious adverse events.
conclusionSaroglitazar 4 mg daily was associated with significant improvements in liver stiffness, steatosis, transaminases, and lipid parameters over 52 weeks. These findings support its hepatometabolic potential across both early and advanced MASLD/MASH stages in real-world practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.